Triple Therapy With Tegoprazan in H. Pylori Positive Patients_PILOT

• Status: Completed
• Trial end date: 2021-01-29
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to compare safety and efficacy in an exploratory manner between a Tegoprazan triple therapy and a RAPAE01 triple therapy in H. pylori positive patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CJ HealthCare Corporation; HK inno.N Corporation
• Treatments: Amoxicillin; Clarithromycin

Criteria

Inclusion Criteria:

• H. pylori positive at screening

• Subjects who have upper gastrointestinal disease

Exclusion Criteria:

• Having received prior therapy for eradication of H. pylori

• Prior use of P-CAB, proton pump inhibitors (PPIs), H2 receptor blockers within 14 days

• Prior use of H. pylori eradication effective antibiotics, bismuth within 28 days